HealthDay News — Prehospitalization statin use is associated with lower inpatient mortality among patients hospitalized with COVID-19, according to research published online Feb. 26 in Nature Communications.
Aakriti Gupta, MD, from New York-Presbyterian Hospital and the Columbia University Irving Medical Center in New York City, and colleagues analyzed data from 2626 patients admitted with COVID-19 from February 1 through May 12, 2020, with follow-up ending June 11, 2020. Using data from electronic medical records, the authors assessed previous statin use.
The researchers found that 36.2% of participants were antecedent statin users. In a propensity score-matched cohort of 1296 patients (648 statin users and 648 nonusers), statin use was associated with significantly lower odds of the primary end point of in-hospital mortality within 30 days (odds ratio, 0.47), with the primary end point occurring in 14.8% and 26.5% of patients receiving statins and those not receiving statins, respectively. The secondary endpoint of invasive mechanical ventilation at 30 days occurred in 18.6% and 21.9% of patients receiving statins and those not receiving statins, respectively (odds ratio, 0.76).
“If their beneficial effect bears out in randomized clinical trials, statins could potentially prove to be a low-cost and effective therapeutic strategy for COVID-19,” a coauthor said in a statement.